Table 1.
Baseline characteristics of the study cohort.
| Variables | Overall (n = 485) | No-DNMT3A/TET2VAF≥2% (n = 425) | DNMT3A/TET2VAF≥2% (n = 60) | P-value |
|---|---|---|---|---|
| Age, years | 61.8 ± 12.0 | 61.1 ± 12.0 | 66.5 ± 10.7 | 0.001 |
| Age <50 years, n (%) | 74 (15.3) | 72 (16.9) | 2 (3.3) | 0.006 |
| Female, n (%) | 133 (27.4) | 108 (25.4) | 25 (41.7) | 0.008 |
| Coronary risk factors | ||||
| Hypertension, n (%) | 224 (46.2) | 192 (45.2) | 32 (53.3) | 0.24 |
| Dyslipidemia, n (%) | 321 (66.2) | 287 (67.5) | 34 (56.7) | 0.096 |
| Diabetes mellitus, n (%) | 110 (22.7) | 90 (21.2) | 20 (33.3) | 0.035 |
| Cigarette smoking | 0.81 | |||
| Non-smoker, n (%) | 162 (33.4) | 142 (33.4) | 20 (33.3) | |
| Former smoker, n (%) | 68 (14.0) | 58 (13.6) | 10 (16.7) | |
| Current smoker, n (%) | 255 (52.6) | 225 (52.9) | 30 (50.0) | |
| BMI, kg/m2 | 24.5 (22.5–26.8) | 24.6 (22.5–26.9) | 24.2 (22.4–26.5) | 0.37 |
| CKD, n (%) | 27 (5.6) | 25 (5.9) | 2 (3.3) | 0.61 |
| Family history of CHD, n (%) | 71 (14.6) | 60 (14.1) | 11 (18.3) | 0.39 |
| Previous history | ||||
| Prior MI, n (%) | 11 (2.3) | 9 (2.1) | 2 (3.3) | 0.90 |
| Prior PCI, n (%) | 17 (3.5) | 15 (3.5) | 2 (3.3) | 1.00 |
| LVEF, % | 58 (51–61) | 58 (51–61) | 57 (49–62) | 0.73 |
| Laboratory data | ||||
| hs-CRP, mg/l | 6.39 (2.43–12.12) | 6.27 (2.37–12.00) | 7.87 (3.22–13.25) | 0.13 |
| NT-proBNP, pg/ml | 226 (110–776) | 220 (109–692) | 426 (125–1774) | 0.093 |
| Peak Troponin I, ng/ml | 54 (23–131) | 55 (23–125) | 50 (21–154) | 0.78 |
| White blood count, 103/μl | 11.5 ± 4.0 | 11.5 ± 4.0 | 11.6 ± 3.9 | 0.84 |
| Haemoglobin, g/dl | 14.4 ± 2.0 | 14.4 ± 2.0 | 14.0 ± 1.9 | 0.13 |
| Platelet count, 103/μl | 233 ± 67 | 234 ± 67 | 226 ± 67 | 0.43 |
| TC, mg/dl | 179 ± 41 | 179 ± 42 | 173 ± 37 | 0.23 |
| Triglyceride, mg/dl | 123 (88–176) | 125 (89–178) | 109 (81–158) | 0.21 |
| LDL-C, mg/dl | 110 ± 36 | 111 ± 36 | 104 ± 32 | 0.15 |
| HDL-C, mg/dl | 49 ± 12 | 48.6 ± 12.5 | 48.9 ± 12.4 | 0.85 |
| HbA1c, % | 5.8 (5.5–6.2) | 5.8 (5.4–6.1) | 5.9 (5.6–6.9) | 0.031 |
| Creatinine, mg/dl | 1.03 (0.86–1.18) | 1.03 (0.87–1.18) | 1.03 (0.81–1.16) | 0.17 |
| Procedural characteristics | ||||
| Extent of coronary artery disease | 0.69 | |||
| 1-vessel disease, n (%) | 36 (7.4) | 33 (7.8) | 3 (5.0) | |
| 2-vessel disease, n (%) | 90 (18.6) | 81 (19.1) | 9 (15.0) | |
| 3-vessel disease, n (%) | 359 (74.0) | 311 (73.2) | 48 (80.0) | |
| SYNTAX score | 27.6 ± 11.4 | 27.5 ± 11.6 | 28.5 ± 10.2 | 0.55 |
| Total ischemic time, hour | 5.0 (3.0–7.5) | 5.0 (3.0–7.5) | 5.0 (3.5–7.0) | 0.67 |
| Pre-hospital fibrinolysis, n (%) | 20 (4.1) | 17 (4.0) | 3 (5.0) | 0.99 |
| Type of PCI | ||||
| Primary PCI, n (%) | 438 (90.3) | 383 (90.1) | 55 (91.7) | 0.65 |
| Rescue PCI, n (%) | 5 (1.0) | 4 (0.9) | 1 (1.7) | |
| Delayed PCI, n (%) | 42 (8.7) | 38 (8.9) | 4 (6.7) | |
| Timely reperfusion, n (%) | 412 (84.9) | 361 (84.9) | 51 (85.0) | 0.99 |
| Thrombus aspiration, n (%) | 130 (26.8) | 115 (27.1) | 15 (25.0) | 0.74 |
| Number of stents | 1.29 ± 0.58 | 1.29 ± 0.59 | 1.28 ± 0.52 | 0.89 |
| Mean stent size | 3.13 ± 0.40 | 3.13 ± 0.41 | 3.08 ± 0.39 | 0.35 |
| Total stent length | 35.3 ± 17.8 | 35.2 ± 17.9 | 36.1 ± 17.6 | 0.72 |
| Medication at discharge | ||||
| Aspirin (%) | 479 (98.8) | 420 (98.8) | 59 (98.3) | 0.55 |
| Clopidogrel (%) | 178 (36.7) | 154 (36.2) | 24 (40.0) | 0.57 |
| Ticagrelor (%) | 303 (62.5) | 268 (63.1) | 35 (58.3) | 0.48 |
| Statins (%) | 479 (98.8) | 420 (98.8) | 59 (98.3) | 0.55 |
| β-blocker (%) | 323 (66.6) | 279 (65.6) | 44 (73.3) | 0.24 |
| ACEI (%) | 269 (55.5) | 236 (55.5) | 33 (55.0) | 0.94 |
| ARB (%) | 9 (1.9) | 8 (1.9) | 1 (1.7) | 1.00 |
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CHD = coronary heart disease; CKD = chronic kidney disease; HbA1c = Hemoglobin A1C; HDL-C = high-density lipoprotein cholesterol; hs-CRP = hyper-sensitivity C-reactive protein; LDL-C = low-density lipoprotein cholesterol; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NT-proBNP = N-terminal pro brain natriuretic peptide; PCI = percutaneous coronary intervention; SYNTAX = Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TC = total cholesterol.